Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients

European Respiratory Journal

Volumn 10, Issue 10, 1997, Pages 2307-2311

  Bargon, J ^a   Viel, K ^a   Dauletbaev, N ^a   Wiewrodt, R ^a   Buhl, R ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Airways obstruction; Cystic fibrosis; Long acting 2 agonists; Short acting 2 agonists

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; SALMETEROL;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; BODY PLETHYSMOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PRIORITY JOURNAL; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; CROSS-OVER STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PROGNOSIS; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0030670517     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10102307     Document Type: Article

References (39)

1. Boat TF, Welsh MJ, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AI, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, McGraw-Hill, 1989; pp. 2649-2680.
2. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150: 448-454.
3. Hodson ME. Respiratory system: adults. In: Hodson ME, Geddes DM, eds. Cystic Fibrosis. London, Chapman & Hall, 1995; pp. 237-257.
4. Ormerod LP, Thomson RA, Anderson CM, Stableforth DE. Reversible airway obstruction in cystic fibrosis. Thorax 1980; 35: 768-772.
5. Tobin MJ, Maguire O, Reen D, Tempany E, Fitzgerald MX. Atopy and bronchial reactivity in older patients with cystic fibrosis. Thorax 1980; 35: 807-813.
6. Thomashefski JF, Abramowsky CR. The pathology of cystic fibrosis. In: Davis PB, ed. Cystic Fibrosis. New York, Marcel Dekker, 1993; pp. 435-489.
7. Cropp GJ. Effectiveness of bronchodilators in cystic fibrosis. Am J Med 1996; 100: 19S-29S.
8. Hordvik NL, König P, Morris D, Kreutz C. Barbero GJ. A longitudinal study of bronchodilator responsiveness in cystic fibrosis.Am Rev Respir Dis 1985; 131: 889-893.
9. Eggleston PA, Rosenstein BJ, Stockhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991; 99: 1088-1092.
10. König P, Gayer D, Barbero GJ, Shaffer J. Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. Pediatr Pulmonol 1995; 20: 205-214.
11. Hordvik NL, Sammut PH, Judy CG, Strizek SJ, Colombo JL. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 156-160.
12. Zach MS, Obcrwaldner B, Forche G, Polgar G. Bronchodilators increase airway instability in cystic fibrosis. Am Rev Respir Dis 1985; 131: 537-543.
13. Reaburn D. Bronchodilator therapy in cystic fibrosis: for better or worse. Med Hypotheses 1988; 26: 59-62.
14. Zinman R, Wohl MEB, Ingram RH. Nonhomogenous lung emptying in cystic fibrosis patients. Am Rev Respir Dis 1991; 143: 1257-1261.
15. Rabe KF, Jörres R, Nowak D, Behr N, Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993; 147: 1436-1441.
16. Ullmann A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. Am Rev Respir Dis 1990; 142: 571-575.
17. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327: 1420-1425.
18. Pearlman DS, Liddle R. Controlling asthma symptoms: salmeterol compared with salbutamol in large-scale, multicentre studies. Eur Respir Rev 1994; 21: 301-305.
19. Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336: 1338-1342.
20. British Thoracic Society. Guidelines on the management of asthma. Thorax 1993; 48 (Suppl. 2): S1-S24.
21. National Heart, Lung and Blood Institute. National Institutes of Health. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. NIH publication No. 95-3659. Bethesda, MD, US Department of Health and Human Services, 1995.
22. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
23. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
24. Faurschou P, Steffensen I, Jacques L. Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. Eur Respir J 1996; 9: 1885-1890.
25. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89: 357-362.
26. Grove A, Lipworth BJ, Reid P, et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996; 51: 689-693.
27. Jones PW, Bosh TK, in association with an international study group. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
28. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Coal and Steel Community. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6 (Suppl. 16): 5-40.
29. Dekker FW, Schrier AC, Sterk PJ, Dijkman JH. Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction. Thorax 1992; 47: 162-166.
30. Brooks SM, Ayer H, Discher DP, et al. Surveillance for respiratory hazards in the occupational setting. Am Rev Respir Dis 1982; 127: 952-956.
31. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNAse in exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-642.
32. Kesten S, Chapman KR, Broder I, et al. A three month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991; 144: 622-625.
33. Wood RE, Wanner A, Hirsch J, Farrell PM. Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline. Am Rev Respir Dis 1975; 111: 733-738.
34. Fuller R. Safety of salmeterol in the treatment of asthma. Eur Respir Rev 1995; 27: 133-137.
35. Congleton J, Hodson ME, Duncan-Skingle F. Quality of life in adults with cystic fibrosis. Thorax 1996; 51: 936-940.
36. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396.
37. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996; 153: 65-69.
38. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996; 335: 841-847.
39. 2-agonists. Thorax 1996; 51: 1051-1056.